A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study) - A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study)

Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University0 个研究点目标入组 30 人开始时间: 2014年8月8日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Multiple primary cancers with disease-free period less than 5-years, except carcinoma in situ or intra mucosal disease cured by local therapy 2) Past history of severe hypersensitivity to drug 3) Active incection 4) Fever more than 38 degree 5) Central nervous system metastasis or carcinomatous meningitis 6) Massive cardiac effusion, pleural effusion or ascites 7) Peripheral sensory neuropathy : grade 2 or above (CTCAE v4.0) 8) Chronic daily treatment with oral or intravenous corticosteroids 9) Unstable angina or past history of myocardinal infraction in 6 months 10) Evidence of any other serious disease ; renal failure, hepatic failure, interstinal pneumonitis or lung fibrosis 11) Pregnant, lactating female, female of childbearing potential or male without contracepcion intention 12) Psychiatric disease that is inapprocpriate for entry into this study 13) Any patients judged by the investigator to be unfit to participate in the study

发起方

Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University